Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline
Comprehensive clinical development programs being initiated for each investigational candidate
Comprehensive clinical development programs being initiated for each investigational candidate
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Subscribe To Our Newsletter & Stay Updated